NRX Pharmaceuticals, Inc. Warrant (NRXPW)

• Market cap: $1.31M
• 1 day: -10%
• 5 days: 0%
• 1 month: -0.11%
• 3 months: 11.94%
• 6 months: -7.79%
• Year to date: -52.63%
• 1 year: 0%
• 5 years: -64%
• 10 years: -74.43%
• Sector: Healthcare
• Industry: Biotechnology

About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.08% less ownership

Funds ownership: 0.51% [Q1] → 0.43% (-0.08%) [Q2]

14% less capital invested

Capital invested by funds: $6.16K [Q1] → $5.3K (-$862) [Q2]

25% less funds holding

Funds holding: 4 [Q1] → 3 (-1) [Q2]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1